OUR RESEARCH CENTER
About 20 millions euros per annum are invested in our Research Center in basic research.
Digna Biotech is a biotechnological company dedicated to the development and exploitation of the research products generated by the Center of Applied Medical Research (Centro de Investigación Médica Aplicada, CIMA) in Pamplona.
The goal of the company is to lead the development of preclinical studies and clinical trials originating from intellectual property generated by its investigators.
CIMA is one of the most important private biomedical research center, with more than 300 researchers.
NEWS
- 25-03-2010
- Disitertide (P144), jointly developed by ISDIN and Digna Biotech showed a statistically significant improvement versus placebo in the patients that perceived improvement of the treated skin area affected by systemic sclerosis
- 19-01-2010
- Digna Biotech starts the clinical research phase with interferon alpha-5 in patients with genotype 1 chronic hepatitis C that have not healed with previous treatment
- 10-09-2009
- Biotecnol, Digna Biotech and Genentech enter into an Exclusive License and Option Agreement, for treatment of life-threatening liver diseases
- 15-05-2009
- Cardiotrophin-1 showed to improve survival in a rabbit model of fulminant hepatic failure (FHF) of viral origin.
- 28-07-2008
- Biotecnol and Digna Biotech extend their existing collaboration on the development of Cardiotrophin-1 through an exclusive marketing, promotion and option agreement
- 08-05-2008
- Digna Biotech and Aachen Resonance signed an agreement for the joint development of drug eluting devices.
- 21-05-2007
- Biotecnol and Digna Biotech to collaborate on the development of Cardiotrophin-1 for organ transplantation
© Digna Biotech · Legal Information
Development: Interesa Consultores S.A.